TMT1A and sarcoma: Further studies showed that METTL7A was highly accurate in the prediction of 12 cancers, and the low expression of METTL7A significantly correlated with the worst overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in kidney renal clear cell carcinoma (KIRC), mesothelioma (MESO) and sarcoma (SARC).